Cytidine deaminases APOBEC3C and APOBEC3D promote DNA replication stress resistance in pancreatic cancer cells

Ubhi, Tajinder and Zaslaver, Olga and Quaile, Andrew T. and Plenker, Dennis and Cao, Pinjiang and Pham, Nhu-An and Békési, Angéla and Jang, Gun-Ho and O’Kane, Grainne M. and Notta, Faiyaz and Moffat, Jason and Wilson, Julie M. and Gallinger, Steven and Vértessy, Beáta (Grolmuszné) and Tuveson, David A. and Röst, Hannes L. and Brown, Grant W. (2024) Cytidine deaminases APOBEC3C and APOBEC3D promote DNA replication stress resistance in pancreatic cancer cells. NATURE CANCER, 5 (6). pp. 895-915. ISSN 2662-1347

Preview

Text UbhiT_2024_NatCancer.pdf - Published Version Download (22MB) | Preview

Abstract

Gemcitabine is a potent inhibitor of DNA replication and is a mainstay therapeutic for diverse cancers, particularly pancreatic ductal adenocarcinoma (PDAC). However, most tumors remain refractory to gemcitabine therapies. Here, to define the cancer cell response to gemcitabine, we performed genome-scale CRISPR–Cas9 chemical–genetic screens in PDAC cells and found selective loss of cell fitness upon disruption of the cytidine deaminases APOBEC3C and APOBEC3D. Following gemcitabine treatment, APOBEC3C and APOBEC3D promote DNA replication stress resistance and cell survival by deaminating cytidines in the nuclear genome to ensure DNA replication fork restart and repair in PDAC cells. We provide evidence that the chemical–genetic interaction between APOBEC3C or APOBEC3D and gemcitabine is absent in nontransformed cells but is recapitulated across different PDAC cell lines, in PDAC organoids and in PDAC xenografts. Thus, we uncover roles for APOBEC3C and APOBEC3D in DNA replication stress resistance and offer plausible targets for improving gemcitabine-based therapies for PDAC. © The Author(s), under exclusive licence to Springer Nature America, Inc. 2024.

Actions (login required)

Edit Item